

Psychopharmacology: How Drugs Affect Behavior (PSYC 362)

Mr. John E. Kelsey
Office: Pettengill 359 (6184)

Winter, 2011
8:00 MWF

Office Hours: 9-10 T & 9:30-11:30 Th
and by appointment

Required Text: Meyer, J. M., & Quenzer, L. F. (2005). *Psychopharmacology: Drugs, the Brain, and Behavior*. Sunderland, MA: Sinauer.

Reserved Reading: On back

- Jan. 10 **Introduction**
12 **Basic Pharmacology:** Pharmacokinetics and pharmacodynamics (Ch 1, esp. 21-31)
14 **Basic Neuroscience:** Nerve action potentials and synaptic transmission (Ch 2, esp. 40-47; Ch 3)
21 **Acetylcholine and Alzheimer's** (Ch 6, 140-151; Marighetto et al., 2008)
24 **Dopamine, Parkinson's, and Norepinephrine** (Ch 5; Schapira, 2008; Kelsey et al., 2009) **Quiz**
28 **Serotonin, Glutamate, and GABA** (Ch 6, 151-160; Ch 7; Ch 14, 358-363; Didriksen et al., 2007)
31 **Drug Classification and Schedules; Anxiolytics/Sedatives** (Ch 1, 22-23; Chs 4 & 17; Low et al., 2000; Davis et al., 2005; Kindt et al., 2009)
- Feb. 4 **Alcohol** (Ch 9; Gross et al., 2001; Maisto et al., 2004)
- 11* **Exam 1**
- 9 **Stimulants: Cocaine and Amphetamine** (Ch 11; Tahsili-Fahadan et al., 2010; Fiorino & Phillips, 1999)
14 **Nicotine and Caffeine** (Ch 12; Bannon et al., 1998; Rollema et al., 2007)
18 **Opiates:** Pain (Ch 10, 246-260; Fields, 2009)
28* **Addiction** (Ch 10, 260-272; Redila & Chavkin, 2008)
- Mar. 7 **Addiction:** Dopamine hypothesis (Ch 8; Koya et al., 2009) **Paper 1 due**
9 **Role of conditioning/learning** (Siegel, 2008; Kenny, 2007)
11 **Treatment** (Sigmon, 2007)
14 **Marijuana and Cannabinoids** (Ch 13; Murray et al., 2007)
- 16 **Exam 2**
- 18 **Antipsychotics:** Dopamine hypothesis (Ch 18; Javitt & Coyle, 2003; Harvey et al., 2003)
21 **Glutamate hypothesis** (Ch 14, 358-363; Didriksen et al., 2007)
23 **Antidepressants:** Norepinephrine and serotonin (Ch 16; Blier & de Montigny, 1998; Arkowitz & Lilienfeld, 2007; Li et al., 2010)
25 **Bipolar disorder** (Goldberg, 2007; Emilien et al., 1996)
28 **Attention Deficit Disorder (ADD & ADHD) and Cognitive Enhancers** (Pelham et al., 2005; Stix, 2009)
30 **Hallucinogens, Inhalents, and Others** (Chs 14 & 15; Vollenweider & Kometer, 2010)
- April 1 **Drug Development** (Zivin, 2000; Miller, 2010)
4 - 6 **Student Presentations: Policy and ethical issues**
8 **Placebo Effects** (Colloca & Benedetti, 2005) **Paper 2 due**
- 14 **Final Exam: 8:00 AM**

***I will be out of town on February 11 and March 4**

Tentative Grading Percentages

Quiz	5%	Presentation/Paper 2	12.5%
Exam 1	15%	Homework and class participation	5%
Paper 1	12.5%	Comprehensive Final Exam	30%
Exam 2	20%		100%

References

- Arkowitz, H., & Lilienfeld, S. O. (October/November, 2007). The best medicine? *Scientific American Mind*, 80-83.
- Bannon, A. W., Decker, M. W., Holladay, M. W., Curzon, P., Donnelly-Roberts, D., Puttfarcken, P. S., Bitner, R. S., Diaz, A., Dickenson, A. H., Porsolt, R. D., Williams, M., & Arneric, S. P. (1998). Broad spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. *Science*, 279, 77-81.
- Blier, P., & de Montigny, C. (1998). Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses. *Biological Psychiatry*, 44, 313-323.
- Colloca, L., & Benedetti, F. (2005). Placebos and painkillers: is mind as real as matter? *Nature Reviews Neuroscience*, 6, 545-552.
- Davis, M., Myers, K. M., Ressler, K. J., & Rothbaum, B. O. (2005). Facilitation of extinction of conditioned fear by D-cycloserine. *Current Directions in Psychological Science*, 14, 214-218.
- Didriksen, M., Skarsfeldt, T., & Arnt, J. (2007). Reversal of PCP-induced learning and memory deficits in the Morris' water maze by sertindole and other antipsychotics. *Psychopharmacology*, 193, 225-233.
- Emilien, G., Maloteaux, J. M., Seghers, A., & Charles, G. (1996). Lithium compared to valproic acid and carbamazepine in the treatment of mania: a statistical meta-analysis. *European Neuropsychopharmacology*, 6, 245-252.
- Fields, R. D. (November, 2009). New culprits in chronic pain. *Scientific American*, 50-57.
- Fiorino, D. F., & Phillips, A. G. (1999). Facilitation of sexual behavior in male rats following d-amphetamine-induced behavioral sensitization. *Psychopharmacology*, 142, 200-208.
- Goldberg, J. F. (2007). What constitutes evidence-based pharmacotherapy for bipolar disorder? Part 1: first-line treatments. *Journal of Clinical Psychiatry*, 68, 1982-1983.
- Gross, A. M., Bennett, T., Sloan, L., Marx, B. P., & Juergens, J. (2001). The impact of alcohol and alcohol expectancies on male perception of female sexual arousal in a date rape analog. *Experimental and Clinical Psychopharmacology*, 9, 380-388.
- Harvey, P. D., Green, M. F., McGurk, S. R., & Meltzer, H. Y. (2003). Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. *Psychopharmacology*, 169, 404-411.
- Javitt, D. C., & Coyle, J. T. (January, 2004). Decoding schizophrenia. *Scientific American*, 290, 48-55.
- Kelsey, J. E., Harris, O., & Cassin, J. (2009). The CB₁ antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease. *Behavioural Brain Research*, 203, 304-307.
- Kenny, P. J. (2007). Brain reward systems and compulsive drug use. *Trends in Pharmacological Sciences*, 28, 135-141.
- Kindt, M., Soeter, M., & Vervliet, B. (2009). Beyond extinction: erasing human fear responses and preventing the return of fear. *Nature Neuroscience*, 12, 256-258.
- Koya, E., Golden, S. A., Harvey, B. K., Guez-Barber, D. H., Berkow, A., Simmons, D. E., Bossert, J. M., Nair, S. G., Uejima, J. L., Marin, M. T., Mitchell, T. B., Farquhar, D., Ghosh, S. C., Mattson, B. J., & Hope, B. T. (2009). Targeted disruption of cocaine-activated nucleus accumbens neurons prevents context-specific sensitization. *Nature Neuroscience*, 12, 1069-1073.
- Low, K., Crestani, F., Keist, R., Benke, D., Brunig, I., Benson, J. A., Fritschy, J., Rulicke, T., Bluethmann, H., Mohler, H., & Rudolph, U. (2000). Molecular and neuronal substrate for the selective attenuation of anxiety. *Science*, 290, 131-134.
- Li, N., Lee, B., Liu, R. J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X. Y., Aghajanian, G., & Duman, R. S. (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. *Science*, 329, 959-964.
- Maisto, S. A., Carey, M. P., Carey, K. B., Gordon, C. M., & Schum, J. L. (2004). Effects of alcohol and expectancies on HIV-related risk perception and behavioral skills in heterosexual women. *Experimental and Clinical Psychopharmacology*, 12, 288-297.
- Marighetto, A., Valerio, S., Desmedt, A., Philippin, J. N., Trocme-Thibierge, C., & Morain, P. (2008). Comparative effects of the alpha7 nicotinic partial agonist, S 24795, and the cholinesterase inhibitor, donepezil, against aging-related deficits in declarative and working memory in mice. *Psychopharmacology*, 197, 499-508.
- Miller, G. (2010). Is pharma running out of brainy ideas? *Science*, 329, 502-504.
- Murray, R. M., Morrison, P. D., Henquet, C., & Di Forti, M. (2007). Cannabis, the mind and society: the hash realities. *Nature Reviews Neuroscience*, 8, 885-895.
- Pelham, W. E., Burrows-Maclean, L., Gnagy, E. M., Fabiano, G. A., Coles, E. K., Tresco, K. E., et al. (2005). Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD. *Experimental and Clinical Psychopharmacology*, 13, 111-126.
- Redila, V. A., & Chavkin, C. (2008). Stress-induced reinstatement of cocaine seeking is mediated by the kappa opioid system. *Psychopharmacology*, 200, 59-70.
- Rollema, H., Coe, J. W., Chambers, L. K., Hurst, R. S., Stahl, S. M., & Williams, K. E. (2007). Rationale, pharmacology and clinical efficacy of partial agonists of α 4 β 2 nACh receptors for smoking cessation. *Trends in Pharmacological Sciences*, 28, 316-325.
- Schapira, A. H. (2009). Neurobiology and treatment of Parkinson's disease. *Trends in Pharmacological Sciences*, 30, 41-47.
- Sigmon, S. C. (2007). Investigating the pharmacological and nonpharmacological factors that modulate drug reinforcement. *Experimental and Clinical Psychopharmacology*, 15, 1-20.
- Siegel, S. (2008). Learning and the wisdom of the body. *Learning & Behavior : A Psychonomic Society Publication*, 36, 242-252.
- Stix, G. (October, 2009). Turbocharging the brain. *Scientific American*. 46-55.
- Tahsili-Fahadan, P., Malcolm, R., & Aston-Jones, G. (2010). Modafinil: an anti-relapse medication. *Neuropsychopharmacology*, 35, 343-344.
- Vollenweider, F. X., & Kometer, M. (2010). The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders. *Nature Reviews Neuroscience*, 11, 642-651.
- Zivin, J. A. (April, 2000) Understanding clinical trials. *Scientific American*, 69-75.